Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc. maintains a major clinical focus on cystic fibrosis, with studies spanning long-term treatment evaluation and combination regimens built around CFTR modulator therapies. Research activity includes interest in both established and newer treatment approaches across a broad age range, including infants, children, adolescents, and adults.

• CFTR modulation
• Long-term safety
• Pediatric cystic fibrosis
• Combination therapy

Its cystic fibrosis portfolio reflects sustained attention to respiratory disease management and disease-modifying therapy development.